A vanadium/aspirin complex controlled release using a poly(beta-propiolactone) film. Effects on osteosarcoma cells

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Cancer Therapeutics

Background:

• Developing effective drug delivery systems is crucial for targeted cancer therapy.
• Vanadium compounds have shown potential anticancer properties but require safe delivery methods.
• Poly(beta-propiolactone) (PbetaPL) offers a biodegradable platform for drug encapsulation.

Purpose of the Study:

• To develop and characterize a PbetaPL film-based delivery system for a vanadium-aspirin complex (VOAspi).
• To evaluate the release kinetics and in vitro anticancer efficacy of VOAspi delivered via PbetaPL films.
• To assess the cytotoxicity of the polymer-embedded VOAspi compared to the free drug.

Main Methods:

• PbetaPL films were prepared with varying molecular weights and drug loads.
• Vanadium release kinetics were studied over 7 days.
• In vitro anticarcinogenic effects were evaluated using UMR106 osteosarcoma cells.
• Lipid peroxidation was assessed via thiobarbituric acid reactive substances (TBARS) assay.

Main Results:

• Sustained release of vanadium over 7 days was achieved.
• Drug release was governed by both diffusion and polymer erosion.
• VOAspi-PbetaPL films inhibited osteosarcoma cell proliferation in a dose-dependent manner.
• The polymer-embedded VOAspi demonstrated reduced cytotoxicity and lipid peroxidation compared to free VOAspi.

Conclusions:

• PbetaPL films provide a viable sustained delivery system for vanadium-aspirin complex.
• The developed system effectively delivers VOAspi, retaining its antiproliferative activity with lower cytotoxicity.
• This PbetaPL-based drug delivery system shows promise for biomedical and therapeutic applications in cancer treatment.